Suraksha Diagnostic Q1 FY26 Concall Decoded: From Blood Tests to Genomics Blockbusters
1. Opening Hook
Suraksha Diagnostics just pulled the classic Bollywood plot twist—what began as a neighborhood blood test chain is now moonwalking into genomics and fetal medicine. With 58 centers, a ₹22 Cr shiny genomics lab, and a Fetomat baby-care acquisition, they’re pitching themselves as “Eastern India’s Apollo.” But before we break into applause—remember, volumes grew 26%, revenues 19%, and per-patient revenues actually fell. Translation: more needles, less money per poke.
2. At a Glance
Revenue ₹73.5 Cr (+19%) – Growth faster than a diabetic’s sugar levels.
EBITDA ₹24.6 Cr (+13.5%) – Still healthy, but slightly anemic.
EBITDA Margin 34% – Diagnostic chains love 30–35%, investors love 40+.
PAT ₹9.2 Cr (+20%) – Profit stable like an ECG beep.
Genomics Lab ₹22 Cr capex – First of its kind in Eastern India. Future or fancy? TBD.
3. Management’s Key Commentary
Quote: “Acquired 63% stake in Fetomat Wellness.” (Translation: Pregnancy care = big business, we want our share of the baby shower cake.)
Quote: “Launched Suraksha Genomics, East India’s first full-stack genomic lab.” (Translation: We now sell futuristic tests you can’t pronounce but will still pay for.)
Quote: “Volume grew 26%, revenue per patient fell.” (Translation: More blood taken, but less paisa per drop.)
Quote: “B2B mix rising, impacting realizations.” (Translation: Corporates love package deals, margins hate them.)
Quote: “All mature centers >2 years have 37% EBITDA margins.” (Translation: Old centers mint, new ones bleed.)
Quote: “Plan 15–18 new centers in FY26.” (Translation: Expansion first, margins later. Classic desi growth strategy.)
